In clinical samples, JMJD6 and EZH2 expression significantly correlated in both normal and tumor samples, however the strongest correlation was observed in triple-negative breast cancer (TNBC) subtype. This evidence concerns the gene JMJD6 and triple-negative breast carcinoma.